NCT00683891View on ClinicalTrials.gov

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

CompletedOBSERVATIONAL

Timeline

Start Date

Not specified

Conditions

Weight GainSialorrhea

Interventions

DRUG

FazaClo (clozapine, USP) ODT

Trial Locations (2)

28054

Gihwala & Associates, Gastonia

92626

Pacific Neuropsychiatric Specialists, Costa Mesa

Sponsors

Lead Sponsor

Azur Pharma, Inc

All Listed Sponsors

lead

Azur Pharma, Inc

INDUSTRY

NCT00683891 - FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey | Biotech Hunter | Biotech Hunter